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CHCHD2 inhibits apoptosis by interacting with Bcl-x L
to regulate Bax activation
Y Liu1,2,3,6, HV Clegg1,2,4,6, PL Leslie1,2,4, J Di1,2,3, LA Tollini1,2,4, Y He1,2,4, T-H Kim1,2, A Jin1,2, LM Graves5, J Zheng3 and Y Zhang*,1,2,3,5
Mitochondrial outer membrane permeabilization (MOMP) is a critical control point during apoptosis that results in the release of
pro-apoptotic mitochondrial contents such as cytochrome c. MOMP is largely controlled by Bcl-2 family proteins such as Bax,
which under various apoptotic stresses becomes activated and oligomerizes on the outer mitochondrial membrane. Bax
oligomerization helps promote the diffusion of the mitochondrial contents into the cytoplasm activating the caspase cascade. In
turn, Bax is regulated primarily by anti-apoptotic Bcl-2 proteins including Bcl-xL, which was recently shown to prevent Bax from
accumulating at the mitochondria. However, the exact mechanisms by which Bcl-xL regulates Bax and thereby MOMP remain
partially understood. In this study, we show that the small CHCH-domain-containing protein CHCHD2 binds to Bcl-xL and inhibits
the mitochondrial accumulation and oligomerization of Bax. Our data show that in response to apoptotic stimuli, mitochondrial
CHCHD2 decreases prior to MOMP. Furthermore, when CHCHD2 is absent from the mitochondria, the ability of Bcl-xL to inhibit Bax
activation and to prevent apoptosis is attenuated, which results in increases in Bax oligomerization, MOMP and apoptosis.
Collectively, our findings establish CHCHD2, a previously uncharacterized small mitochondrial protein with no known homology to
the Bcl-2 family, as one of the negative regulators of mitochondria-mediated apoptosis.
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Apoptosis is a tightly regulated form of programmed cell death
that is critical for proper embryonic development, tissue
homeostasis and immune response. Aberrant regulation of
apoptosis contributes to a wide range of ailments including
autoimmune disorders, neurodegenerative diseases and
cancer. Unlike necrotic cell death, apoptosis is a genetic
program that is characterized by distinct morphological
features such as membrane blebbing, chromatin condensa-
tion, DNA fragmentation and cell shrinkage.1 In vertebrates,
apoptosis can occur through two pathways: extrinsic, or
receptor-mediated apoptosis, and intrinsic, or mitochondria-
mediated apoptosis. Intrinsic apoptosis is induced by cellular
stressors such as DNA damage, which lead to mitochondrial
outer membrane permeabilization (MOMP), cytochrome
c release from the mitochondrial intermembrane space,
activation of cysteine proteases (caspases) and induction of
apoptosis. Once MOMP occurs, cell death is thought to be
inevitable. Therefore, much research has been devoted to
elucidating the mechanisms and signaling pathways that
govern this critical regulatory point in apoptosis.
MOMP is controlled largely by the B-cell lymphoma 2 (Bcl-2)
family of proteins,2 all of which contain at least one of four
BH (Bcl-2 homology) domains designated BH1–4. During
apoptosis, the pro-apoptotic Bcl-2 proteins Bax and/or Bak
become activated and oligomerize on the mitochondrial outer
membrane3 increasing mitochondrial membrane permeabili-
zation through a mechanism that is not entirely clear. Bax and
Bak are activated by BH3-only Bcl-2 family proteins such as
Bim, t-Bid and Puma.4–13 Conversely, Bax and Bak are
inhibited by pro-survival Bcl-2 family proteins such as Bcl-2,
Mcl-1 and Bcl-xL.2,14–16 Of the pro-survival Bcl-2 family
proteins, Bcl-2 is found at the outer mitochondrial membrane,
whereas Bcl-xL and Mcl-1 localize to the outer mitochondrial
membrane and the mitochondrial matrix.17,18 Matrix-localized
Bcl-xL and Mcl-1 have been shown to promote mitochondrial
respiration,19 suggesting that crosstalk exists between apop-
totic pathways and other mitochondria-based biological
events. Based on this recent discovery, one might reason that
other mitochondrial proteins previously characterized as
structural proteins or metabolism-associated enzymes could
play an additional intermediate role in the regulation of
apoptosis by interacting with Bcl-2 family proteins.
We identified CHCHD2 in a mass spectrometry-based
screen for binding partners of p32, a mitochondrial protein
previously shown by our lab to bind and mediate the apoptotic
effects of the tumor suppressor p14ARF.20 CHCHD2
was subsequently detected in independent screens for
proteins that regulate cellular metabolism and migration;21,22
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however, the functions of CHCHD2 remain unknown.
CHCHD2 is encoded by the chchd2 gene (coiled-coil helix
coiled-coil helix domain-containing 2), which spans 4921 base
pairs, contains 4 exons, and is located on human chromosome
7p11.2, a chromosomal region that is often amplified in
glioblastomas.23 The protein encoded by the chchd2 gene is
ubiquitously expressed24 and is relatively small, as it codes for
only 151 amino acids. CHCHD2 is well-conserved among
different species from humans to yeast, and mouse and
human CHCHD2 share 87% amino acid sequence identity
(Supplementary Figures S1A and S1B). CHCHD2 contains a
C-terminal CHCH (coiled-coil helix coiled-coil helix) domain,
which is characterized primarily by four cysteine residues
spaced 10 amino acids apart from one another (CX(9)C
motif).25 The function of the CHCH domain is not well
understood, and the few characterized proteins that harbor
this domain have diverse functions. Many CHCH domain-
containing proteins localize to the mitochondrial inner mem-
brane or the intermembrane space, including Cox12, Cox17,
Cox19, Cox23, Mia40 (yeast homolog of human CHCHD4),
CHCHD3 and CHCHD6. Cox17 and Cox19 aid in the
assembly of the COX complex,26,27 whereas Mia40/Tim40
has been shown to transport proteins into the mitochondrial
intermembrane space.28,29 Furthermore, CHCHD3 and
CHCHD6 are essential for maintaining the integrity of
mitochondrial cristae and thus mitochondrial function.30–32
Interestingly, a recent report has shown that CHCHD6 is
regulated by DNA damage stress, and alterations in CHCHD6
expression affect the viability of breast cancer cells in
response to genotoxic anticancer drugs.32
Despite advances in our understanding of how MOMP and
apoptosis are regulated by the Bcl-2 family of proteins, much
remains unknown with respect to the mechanisms that
lead to Bax activation and oligomerization particularly
concerning the roles that mitochondria-associated proteins
play in the process. In this study, we characterize the small,
mitochondria-localized protein CHCHD2 as a novel regulator
of Bax oligomerization and apoptosis. Furthermore, we show
evidence that CHCHD2 binds to Bcl-xL at the mitochondria
under unstressed conditions. In response to apoptotic stimuli,
CHCHD2 decreases and loses its mitochondria localization,
which is accompanied by decreased Bcl-xL–Bax interaction
and increased Bax homo-oligomerization and Bax–Bak
hetero-oligomerization. Collectively, our results suggest that
CHCHD2 negatively regulates the apoptotic cascade
upstream of Bax oligomerization.
Results
CHCHD2 localizes to the mitochondria. Computational
analysis indicates that in addition to its C-terminal CHCH
domain, CHCHD2 contains two functional domains: a
canonical mitochondrial-targeting signal at the N terminus
(MitoProt33) and a predicted transmembrane element in the
central domain, (Figure 1a). To determine whether CHCHD2
indeed localizes to the mitochondria, we examined its
subcellular localization by immunofluorescence. U2OS cells
were transfected with plasmids expressing C-terminal FLAG-
tagged CHCHD2, 24 h after which the cells were fixed and
subjected to immunofluorescence staining for FLAG.
CHCHD2–FLAG localized primarily to the mitochondria as
indicated by an overlap with MitoTracker dye signal (Invitro-
gen, Grand Island, NY, USA; Figure 1b). Next, we generated
a rabbit polyclonal antibody specific for CHCHD2, which we
used to confirm the localization of endogenous CHCHD2
protein. Once the antibody specificity to CHCHD2 was
confirmed by western blotting (Supplementary Figure S2A)
and immunofluorescence staining (Supplementary Figure
S2B), immunofluorescence staining for endogenous
CHCHD2 protein was conducted in unstressed U2OS cells.
Similarly to our staining results for FLAG–CHCHD2, endo-
genous CHCHD2 localized primarily to the mitochondria as
revealed by an overlap in signals with the Tim23 mitochon-
drial marker (Figure 1c). CHCHD2 mitochondrial localization
was also observed in HeLa cells (Supplementary Figure S3A)
and mouse embryo fibroblasts (MEFs) (Supplementary
Figure S3B). To further confirm CHCHD2 mitochondrial
localization, we performed a differential detergent subcellular
fractionation, which revealed that CHCHD2 resides in the
mitochondria-enriched heavy membrane fraction consistent
with the immunofluorescence results (Figure 1d).
CHCHD2 is important for cell survival from genotoxic
stress. Because CHCHD2 was identified as a binding
partner of p32, a mitochondrial protein previously shown to
mediate the apoptotic effects of the tumor suppressor
p14ARF,20 we sought to determine whether CHCHD2 might
play a role in cell survival. We first analyzed the effect of
CHCHD2 knockdown using two different siRNA duplexes
targeting different regions of the CHCHD2 transcript. U2OS
cells were treated with nonspecific control siRNA (NS) or one
of two different CHCHD2 siRNA for 48 h, after which the cells
were subjected to various apoptotic stimuli, including UV
irradiation, cisplatin, doxorubicin and staurosporine, to
determine whether a reduction in CHCHD2 might affect cell
survival. While CHCHD2 knockdown caused an insignificant
decrease in cell survival in the absence of apoptotic stimuli
(average 95% viable cells compared with the control;
Figure 2a), CHCHD2 knockdown sensitized U2OS cells to
stress-induced cell death, as determined based on the
number of cells surviving the treatment. When considering
the average number of viable cells in the two CHCHD2
siRNA-treated groups as a percentage of the control group,
UV irradiation reduced cell viability to 64% (Figure 2b),
cisplatin reduced cell viability to 27% (Figure 2c), doxorubicin
reduced cell viability to 54% (Figure 2d) and staurosporine
reduced cell viability to 69% (Figure 2e). The effect of
CHCHD2 knockdown was also assessed in HeLa cells
treated with UV irradiation and cisplatin. Consistent with the
U2OS data, CHCHD2 knockdown sensitized HeLa cells to
cell death induced by UV (average 43% viable cells relative to
control) and cisplatin (average 34% viable cells relative to
control; Supplementary Figure S4). We also determined
whether CHCHD2 overexpression might protect cells from
stress-induced cell death using CHCHD2-expressing adeno-
viruses. U2OS cells were infected with adenoviral particles
expressing either CHCHD2 (Ad-CHCHD2) or GFP as a
negative control (Ad-Ctl), after which the sensitivity of the
cells to UV treatment was assessed. While adenovirus-
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mediated overexpression of CHCHD2 yielded no significant
effect on unstressed cells, CHCHD2 overexpression effectively
protected UV-treated U2OS cells from cell death (89%
survival relative to 51% for the control; Figure 2f). These
results suggest that CHCHD2 protects cells from genotoxic
stress-induced cell death.
CHCHD2 inhibits MOMP and mitochondrial apoptosis.
The pattern of CHCHD2 expression with respect to cell
viability is consistent with the known anti-apoptotic proteins
such as Bcl-2 and Bcl-xL, the inhibition of which does not
cause substantial cell death but sensitizes cells to apoptotic
stimuli.2 This similarity prompted us to further examine
whether CHCHD2 might play a role as an anti-apoptotic
protein specifically through the mitochondria-dependent
apoptotic pathway. In response to UV treatment, increased
cell death was observed in U2OS cells in the presence of
CHCHD2 siRNA (Figure 3a). Consistent with an apoptotic
phenotype, CHCHD2 knockdown promoted a significant
increase in nuclear fragmentation and phosphatidylserine
exposure, both of which are hallmarks of apoptosis
(Figures 3b and c). Western blotting was then conducted to
examine the expression of molecular markers of apoptosis in
UV-treated HeLa cells in the presence or absence of
CHCHD2 knockdown. Our results show that upon UV
treatment, CHCHD2 expression decreases (Figure 3d, com-
pare lanes 1 and 3). Furthermore, the level of UV-induced
cleavage of caspase-3, one of the main proteases involved in
the apoptotic cascade, was significantly increased upon
knockdown of CHCHD2 (Figure 3d). Consistent with this
observation, CHCHD2 knockdown also enhanced UV-
induced cleavage of poly(ADP-ribose) polymerase (PARP),
a substrate of activated caspase-3 during apoptosis34
(Figure 3e). In contrast, CHCHD2 overexpression resulted
in a reduction in PARP cleavage (Figure 3f). Collectively,
these data suggest that CHCHD2 functions as a negative
regulator of apoptosis.
Cytochrome c release from the mitochondria is often used
as readout for MOMP35 and acts as a trigger for the activation
of the caspase cascade, leading to irreversible apoptotic cell
death. To determine whether CHCHD2 is involved in the
regulation of MOMP, cells were treated with either nonspecific
or CHCHD2-specific siRNA for 48 h, after which the cells
were subjected to UV irradiation and then assessed by
Figure 1 CHCHD2 is a CHCH domain-containing protein that localizes to the mitochondria. (a) Schematic representation of the CHCHD2 protein with putative mitochondrial-
targeting signal (MTS), predicted transmembrane domain (TM) and CHCH (coiled-coil-helix coiled-coil helix) domain shown. The CHCH domain is comprised of four evenly
spaced cysteines with the positions indicated. (b) C-terminally tagged CHCHD2–FLAG localizes to the mitochondria in U2OS cells as indicated by co-staining with MitoTracker
dye. CHCHD2–FLAG was detected by immunofluorescence with anti-FLAG antibody. (c) Mitochondrial localization of endogenous CHCHD2 in U2OS cells detected by
immunofluorescence staining using anti-CHCHD2 antibody as demonstrated by co-staining with the mitochondrial inner membrane protein Tim23 (Tim). (d) Subcellular
fractionation of untreated U2OS cells using a differential detergent method shows CHCHD2 present in the mitochondria-enriched heavy membrane fraction (three replicates are
shown). Mitochondrial hsp70 (mtHsp70) is included as a marker for the mitochondrial fraction, and actin is included as a marker for the cytoplasmic fraction
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immunofluorescence for cytochrome c release. Cells in which
cytochrome c was released (indicated by diffuse staining
throughout the cell, Figure 3g) were counted as cells
with increased MOMP. CHCHD2 knockdown significantly
increased the kinetics with which cytochrome c was released,
as a greater percentage of cells stained diffusely for
cytochrome c in the si-CHCHD2-treated cells relative to the
siNS-treated cells at 1 h (3.9 versus 1.2%), 2 h (14 versus 5%),
and 4 h post-UV treatment (35 versus 7.5%) (Figure 3h),
suggesting that CHCHD2 plays a role in preventing UV-
induced MOMP and cytochrome c release.
Bax activation correlates with CHCHD2 exclusion from
the mitochondria. We next sought to identify the mechan-
ism through which CHCHD2 regulates MOMP and apoptosis.
Immunofluorescence staining of cells treated with or without
UV irradiation revealed that CHCHD2 loses its mitochondrial
localization and shows a diffuse distribution in response to
Figure 2 CHCHD2 is important for cell survival. (a–e) CHCHD2 knockdown sensitizes U2OS cells to apoptosis induced by a variety of agents. Cells were treated with the
indicated siRNA targeting CHCHD2 for 48 h, after which the cells were treated with the following apoptotic stimuli: (b) UV (6 mJ/cm2 for 24 h), (c) cisplatin (10 μg/ml for 18 h),
(d) doxorubicin (7.5 μM for 18 h) and (e) staurosporine (200 nM for 18 h). The number of cells that survived each treatment was counted in at least 4 random fields of view under
each condition. The relative survival is shown as a percentage of the siNS control cells from three independent experimental repeats. (si-#1 and si-#2 target two distinct regions of
CHCHD2 mRNA as described in the Experimental Procedures section). Error bars denote the S.E. (f) Overexpression of CHCHD2 protects U2OS cells from apoptosis. Cells
were infected for 24 h with control adenovirus expressing GFP (Ad-Ctl) or adenovirus expressing untagged CHCHD2 (Ad-CHCHD2), after which the cells were treated with UV to
induce apoptosis (6 mJ/cm2 for 24 h). The number of cells that survived the treatment is shown as a percentage of the Ad-GFP-infected control cells
Figure 3 CHCHD2 inhibits mitochondrial apoptosis and MOMP. (a) CHCHD2 knockdown sensitizes U2OS cells to cell death induced by UV (6 mJ/cm2). Phase-contrast
images are shown for cells treated for 48 h with nonspecific siRNA (siNS) or CHCHD2 siRNA (si-CHCHD2) with or without UV treatment. (b) CHCHD2 knockdown enhances UV-
induced nuclear fragmentation in U2OS cells. Representative DAPI staining is shown for U2OS cells treated for 48 h with siNS or si-CHCHD2 followed by UV (6 mJ/cm2 for 24 h)
or cisplatin (10 μg/ml for 24 h) treatment. (c) CHCHD2 knockdown enhances UV-induced phosphatidylserine exposure. U2OS cells were treated with UV (6 mJ/ cm2) for 24 h,
followed by Annexin-V-FITC and PI-double staining. The cells were then analyzed by flow cytometry. FITC-positive or FITC–PI-double positive cells were counted as apoptotic
cells, and the percentages of apoptotic cells from three independent experiments are shown in the graph. The error bars denote the S.E. (d) Caspase-3 cleavage is enhanced in
UV-treated cells upon knockdown of CHCHD2. HeLa cells were transfected with CHCHD2 siRNA (D2) or control siRNA (NS) followed by UV treatment (2.5 mJ/cm2 for 18 h). Cells
were then lysed, resolved by SDS-PAGE and probed by western blot for cleaved caspase-3 and CHCHD2. Actin is shown as a loading control. (e) CHCHD2 knockdown increases
PARP cleavage in response to apoptotic stimuli. HeLa cells were treated with the indicated siRNA for 48 h and then treated with UV (2.5 mJ/cm2 for 18 h) to induce apoptosis.
Actin is shown as a loading control. (f) CHCHD2 overexpression inhibits PARP cleavage in response to apoptotic stimuli. HeLa cells were infected with adenovirus expressing
empty vector (Ctl) or CHCHD2 (D2) for 48 h and then treated with UV (2.5 mJ/cm2 for 18 h) to induce apoptosis. Actin is shown as a loading control. (g, h) CHCHD2 knockdown
increases the rate of MOMP as indicated by cytochrome c release. U2OS cells were pretreated with the caspase inhibitor QVD to prevent post-MOMP cell death and then treated
with the indicated siRNA for 48 h followed by UV irradiation (50 mJ/cm2) for the indicated amount of time. (g) Representative immunofluorescence images are shown for
endogenous cytochrome c. (h) Quantification of cells with diffuse cytochrome c staining as a result of UV irradiation at various time points. Cells were counted in at least four
random fields of view, and more than 400 cells were counted in total. The graph depicts the percentage of diffusely staining cells of the total cells from three independent
experiments. The error bars denote the S.E.
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UV irradiation (Figure 4a), an observation that is supported
by a rapid decrease in CHCHD2 mitochondrial levels
(Supplementary Figure S5). We did not observe a concomi-
tant increase in cytoplasmic CHCHD2 in these samples,
suggesting that mitochondrial CHCHD2 may be degraded or
translocated to other cellular compartments, such as the
nucleus, in response to apoptotic stimuli. Interestingly, we
observed a subset of cells in which mitochondrial CHCHD2
was depleted yet cytochrome c remained in the mitochondria,
whereas no cells were observed in which cytochrome c was
released and CHCHD2 was retained in the mitochondria
(Figure 4b). This observation suggests that the decrease in
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mitochondrial CHCHD2 probably occurs prior to cytochrome
c release. To test this hypothesis, we examined cytochrome
c and CHCHD2 localization in UV-treated U2OS cells and
quantified the percentage of cells displaying diffuse CHCHD2
staining and cytochrome c release at several time points.
Cells were pretreated with the pan-caspase inhibitor Q-VD-
OPh (QVD) to prevent cell death downstream of cytochrome
c release, thereby preserving cells with released cytochrome
c and allowing these cells to be assessed. Cells were treated
with UV irradiation, after which the cells were fixed for
immunofluorescence staining at the indicated time points.
At each time point, we observed a greater percentage of
cells, displaying diffuse CHCHD2 staining than cytochrome c
release (Figure 4c).
Although several models, including ones based on the
opening of the mitochondrial permeability transition pore
(mPTP) and the formation of the cytochrome c-conducting
channel have been proposed to play key roles in MOMP,36 the
vast majority of models explaining MOMP converge at the pro-
apoptotic Bcl-2 family members Bax and/or Bak. Surprisingly,
we noted that in cells exposed to an apoptotic dose of UV
irradiation, Bax activation was observed only in cells in which
Figure 4 Loss of mitochondrial CHCHD2 correlates with Bax activation. (a) Mitochondrial CHCHD2 is depleted in response to apoptotic stimuli. U2OS cells were pretreated
with QVD for 1 h and then treated with UV (6 mJ/cm2) for 24 h where indicated. Endogenous CHCHD2 was detected by immunofluorescence staining. (b) Loss of mitochondrial
CHCHD2 occurs prior to cytochrome c release in response to apoptotic stimuli. Immunofluorescence staining of endogenous CHCHD2 (green) and cytochrome c (red) in
UV-treated (6 mJ/cm2 for 12 h) U2OS cells shows that in some cells cytochrome c remains in the mitochondria after mitochondrial CHCHD2 is depleted (indicated by the arrow).
(c) Loss of mitochondrial CHCHD2 occurs more rapidly than cytochrome c release. U2OS cells were pretreated with the caspase inhibitor QVD (10 μM for 1 h), after which the
cells were treated with UV (6 mJ/cm2) to induce apoptosis and then fixed at the indicated time points. Cells were subjected to immunofluorescence staining for endogenous
CHCHD2 and cytochrome c. The percentage of cells with diffuse CHCHD2 staining and cytochrome c staining was quantified at each time point and are represented on the graph
as the averages of three independent experiments. For each experiment, at least four random fields of view were counted comprising at least 400 cells. Error bars denote the S.E.
(d) Bax activation correlates with the loss of mitochondrial CHCHD2 in U2OS cells. Cells were treated with UV (6 mJ/cm2 for 24 h) to induce apoptosis. Immunofluorescence
staining was performed to detect endogenous CHCHD2 (green) and activated Bax (6A7 antibody, red). Activated Bax is observed only in cells in which mitochondrial CHCHD2 is
depleted. Nuclei were stained with DAPI
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mitochondrial CHCHD2 was lost, whereas cells that retained
mitochondrial CHCHD2 consistently stained negative for
active Bax (Figure 4d). Thus, in cells undergoing apoptosis,
Bax activation correlated strictly with the loss of mitochondrial
CHCHD2, suggesting that mitochondrial CHCHD2 may be
functionally involved in the negative regulation of Bax
activation.
Bcl-xL is important for CHCHD2 to protect cells from
apoptosis. The correlation between the loss of mitochon-
drial CHCHD2 and Bax activation suggests that CHCHD2
likely inhibits apoptosis by controlling Bax activation and
subsequent MOMP. To further investigate this observation,
co-immunoprecipitation (co-IP) experiments were conducted
to determine whether CHCHD2 interacts directly with Bcl-2
family proteins—the best characterized network of proteins
involved in apoptosis regulation. After probing a number of
Bcl-2 family members (Supplementary Figure S6), we found
that endogenous CHCHD2 interacts with ectopically
expressed FLAG–Bcl-xL in reciprocal co-IP experiments
(Figures 5a and b). We were unable to detect endogenous
Bcl-xL–CHCHD2 binding, which might suggest that this
interaction is transient resulting in a small fraction of Bcl-
xL–CHCHD2 binding at any given time. Bcl-xL is an important
negative regulator of apoptosis that functions by inhibiting
Bax and Bak activation.15,37 Based on our observed
interaction between the two anti-apoptotic proteins CHCHD2
and Bcl-xL, we sought to determine to what extent their
interaction might be required to inhibit apoptosis. To this end,
Bcl-xL was overexpressed in the presence or absence of si-
CHCHD2 in cells. Consistent with previous studies, over-
expression of Bcl-xL inhibited UV-induced apoptosis in all
samples tested (Figure 5c: 23.7 versus 11.5% apoptotic cells
in the presence of siNS (black bars), and 35.4 versus 22.7%
apoptotic cells in the presence of si-CHCHD2 (gray bars));
however, knockdown of CHCHD2 reduced the protective
effect of Bcl-xL overexpression (Figure 5c: 11.5% apoptotic
cells in siNS sample versus 22.7% apoptotic cells in si-
CHCHD2 sample). These results suggest that although Bcl-
xL retains the ability to inhibit apoptosis to an extent in the
absence of CHCHD2, CHCHD2 enhances the pro-survival
function of Bcl-xL. Conversely, the anti-apoptotic function of
CHCHD2 is largely ablated upon depletion of Bcl-xL (Figures
5d and e and Supplementary Figure S7), suggesting that the
anti-apoptotic function of CHCHD2 requires Bcl-xL.
Figure 5 Bcl-xL is required for the anti-apoptotic function of CHCHD2. (a, b) CHCHD2 interacts with Bcl-xL. U2OS cells stably expressing nonspecific (sh-NS) or CHCHD2-
specific (sh-CHCHD2) shRNA were transfected with FLAG–Bcl-xL for 24 h and then lysed with 1% CHAPS buffer. Lysates containing 1 mg of total protein were
immunoprecipitated with antibodies against CHCHD2 (a) or FLAG (b). Samples were analyzed by western blotting with the indicated antibodies. Input loading represents 5% of
the total cell lysate used for IP. (c) CHCHD2 enhances, but is not required for, the apoptosis-inhibiting function of Bcl-xL. U2OS cells were treated with siNS or si-CHCHD2 for 48 h,
followed by transient transfection with FLAG–Bcl-xL or empty vector for another 24 h and then were treated by UV irradiation (6 mJ/cm2) for 24 h. The cells were then stained with
Annexin-V–FITC/PI and analyzed by flow cytometry. The means of the percentages of apoptotic cells from three independent experiments are shown, and the error bars denote
the S.E. (d, e) The inhibitory function of CHCHD2 on apoptosis is compromised by knockdown of Bcl-xL. U2OS cells stably expressing transfected CHCHD2 were treated with the
indicated siRNA constructs for 48 h followed by UV irradiation treatment (25 mJ/cm2) for 18 h as indicated. Cells were then stained with Annexin-V–FITC/PI and analyzed by flow
cytometry. (d) The mean of the percentages of apoptotic cells from three independent experiments are shown, and the error bars denote the S.E. (e) The apoptosis inhibition ratio
was calculated based on the apoptosis percentages shown in d. The difference between the percentage of apoptotic cells with CHCHD2 overexpression and the percentage of
apoptotic cells with empty vector was divided by the percentage of apoptosis in cells transfected with empty vector for each UV-treated sample. The error bars denote the S.E.
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CHCHD2 cooperates with Bcl-xL to regulate Bax in
response to apoptotic stimuli. A recent study has shown
that Bcl-xL regulates Bax through a direct binding mechanism
resulting in Bax retrotranslocation from the mitochondria to
the cytosol, which prevents Bax from forming active
oligomers.38 During apoptosis, Bcl-xL–Bax binding is dis-
rupted, and Bax accumulates at the mitochondria resulting in
MOMP and apoptosis.39 Given the functional correlation
between the loss of mitochondrial CHCHD2 and Bax
activation (Figure 4) and the interaction of CHCHD2 with
Bcl-xL, we examined whether CHCHD2 affects the function of
Bcl-xL and Bax. To this end, U2OS cells stably expressing
CHCHD2 shRNA were transfected with HA-Bax and FLAG-
Bcl-xL, and were subjected to immunoprecipitation with an
HA antibody. CHCHD2 knockdown reduced the level of Bcl-
xL–Bax binding by ~40%, suggesting that CHCHD2 is
important but not required for Bcl-xL–Bax interaction
(Figure 6a). Likewise, CHCHD2 knockdown also increased
the presence of Bax protein in the mitochondria-enriched
heavy membrane fraction, particularly after cells were treated
with UV irradiation (Figure 6b, compare lanes 9 and 10 with
11 and 12).
We then examined whether CHCHD2 depletion could affect
Bax activation. Activated Bax can be detected by immuno-
fluorescence staining using anti-Bax 6A7 antibody, which
recognizes an N-terminal epitope hidden in inactive Bax
protein but exposed due to the conformational changes that
occur during Bax activation. To determine whether CHCHD2
affects Bax activation, cells were treated with CHCHD2 siRNA
for 48 h, after which apoptosis was induced by UV irradiation,
and Bax activation was examined by immunofluorescence
staining with anti-Bax 6A7 antibody. CHCHD2 knockdown did
not affect Bcl-xL localization (Supplementary Figure S8) but
significantly increased UV treatment-induced Bax activation,
as indicated by strong immunofluorescence staining of cells
treated with si-CHCHD2 and UV irradiation (Figures 6c and d)
and increased levels of 6A7 antibody-reactive Bax protein by
western blotting (Figure 6e). CHCHD2 knockdown also
increased Bak protein levels and Bax–Bak hetero-oligomer
formation (Figure 6e), suggesting that CHCHD2 is functionally
associated with the activation of Bax and Bak. To directly
examine Bax oligomerization, mitochondriawere isolated from
cells treated with si-CHCHD2 and UV irradiation and then
treated with trypsin, which degrades Bax monomers but not
Bax oligomers.40 As shown in Figure 6f, CHCHD2 knockdown
increased the level of trypsin-resistant Bax. Altogether, our
data suggest that CHCHD2 inhibits apoptosis at least in part
by cooperating with Bcl-xL to regulate Bax.
Discussion
One of the pro-survival functions of Bcl-xL is its ability to
inhibit Bax and Bak-induced formation of pores in the outer
mitochondrial membrane.41 However, the mechanism
through which Bcl-xL regulates Bax and Bak is not
sufficiently understood and has been a subject of debate.
Some recent studies have shown that Bcl-xL inhibits Bax by
promoting Bax retrotranslocation to the cytoplasm.38,42
Furthermore, these studies demonstrated that Bax
continually cycles between the cytoplasm and the mitochon-
dria. In non-apoptotic cells, when Bax arrives at the
mitochondria Bcl-xL binds with Bax to retrotranslocate
Bax to the cytoplasm. During apoptosis, the Bcl-xL–Bax
interaction is disrupted, leading to mitochondrial accumula-
tion and activation of Bax. However, another study has shown
that both Bax and Bcl-xL exist in a dynamic equilibrium
between the cytosol and the mitochondria, and instead of
actively retrotranslocating Bax, Bcl-xL stabilizes and inhibits
a portion of membrane-associated Bax as a result of the
disruption of survival signals.43 In both of these models,
Bcl-xL plays a key role in inhibiting Bax activation by
retrotranslocating Bax to the cytosol or by directly binding
to membrane-bound Bax to inhibit Bax activation.
Our study establishes CHCHD2 as an anti-apoptotic protein
residing in the mitochondria, where it regulates MOMP during
apoptosis. Through a mechanism that is not yet clear,
CHCHD2 interacts with Bcl-xL to regulate Bax localization,
activation and oligomerization. In response to apoptotic
stimuli, CHCHD2 levels decrease in the mitochondria. The
decrease in mitochondrial CHCHD2 levels correlates with a
loss in the ability of Bcl-xL to suppress Bax, thereby allowing
MOMP and apoptosis to proceed (Figure 6g). Our findings
reveal a novel component of the intrinsic apoptosis pathway
and contribute to our knowledge of the physiological events
that take place at the mitochondria with respect to Bax
localization, activation and oligomerization and ultimately
MOMP and apoptosis.
How the interaction between CHCHD2 and Bcl-xL affects
Bcl-xL inhibition of Bax activation remains unclear. Bcl-xL and
Figure 6 CHCHD2 cooperates with Bcl-xL to regulate Bax translocation, oligomerization and activation. (a) CHCHD2 knockdown reduces Bcl-xL–Bax interaction. U2OS cells
stably expressing nonspecific (sh-NS) or CHCHD2-specific (sh-CHCHD2) shRNA were transfected with HA-Bax and FLAG-Bcl-xL for 24 h and then were lysed with 1% CHAPS
buffer. Cell lysates containing 1 mg of total protein were immunoprecipitated with HA-specific antibody. Samples were analyzed by western blotting with the indicated antibodies.
(b) CHCHD2 knockdown increases mitochondrial translocation of Bax. HeLa cells were transfected with the indicated siRNA for 48 h and then were treated with UV irradiation
(25 mJ/cm2 for 3 h) to induce apoptosis. Subcellular fractionation was performed, and the total cell lysates (Total), cytosolic fractions (Cyto) and mitochondrial fractions (Mito) were
analyzed by western blotting with the indicated antibodies. (c, d) CHCHD2 knockdown augments Bax activation. U2OS cells were treated with the indicated siRNA for 48 h
followed by UV irradiation to induce apoptosis (6 mJ/cm2). Cells were fixed 24 h later and stained for activated Bax (6A7). Red staining indicates the presence of activated Bax
accumulated on the mitochondrial surface. (e) CHCHD2 knockdown augments mitochondrial Bak accumulation and Bax–Bak hetero-oligomerization. Mitochondria were enriched
by fractionation and then were lysed with 1% CHAPS lysis buffer. Following lysis, 500 μg of mitochondrial lysate was immunoprecipitated with Bax (6A7) or Bak antibody. Samples
were analyzed by western blotting with the indicated antibodies. (f) CHCHD2 knockdown increases trypsin-resistant, oligomerized Bax (TR-Bax). A trypsin resistance assay was
conducted on isolated mitochondria after treating HeLa cells with the indicated siRNA for 48 h followed by UV irradiation. Mitochondria were treated with trypsin to digest
monomeric Bax, lysed, resolved by SDS-PAGE and then probed by immunoblotting. (g) Schematic depiction of CHCHD2 function. Apoptotic stimuli such as UV induce loss of
mitochondria CHCHD2, thereby facilitating release of Bax from Bcl-xL-dependent inhibition. Bax then accumulates on the mitochondria and forms oligomers to induce MOMPand
apoptosis
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Bax are thought to exist in equilibrium in the cytosol and the
mitochondria, and apoptotic stress can shift this equilibrium to
favor a membrane-bound form of oligomerized Bax.38,43,44
Some evidence suggests that Bax is retrotanslocated by
Bcl-xL through the C-terminal helix of Bcl-xL;38,42 however,
how Bcl-xL itself switches between its soluble form and the
membrane-bound form and howBcl-xLmaintains the dynamic
equilibrium between the cytosol and the mitochondria remain
unknown. In the context of previous studies, our results
identify CHCHD2 as a novel Bcl-xL-interacting protein and
allow us to speculate on a model whereby mitochondria-
localized CHCHD2 interacts with Bcl-xL by a kiss-and-run
interaction to help maintain the proper Bcl-xL equilibrium
between the cytosol and the mitochondrial membrane in the
absence of apoptotic stimuli. In the presence of CHCHD2, a
large portion of Bcl-xL resides at themitochondria where it can
bind and inhibit Bax. However, in response to apoptotic stimuli,
mitochondrial CHCHD2 levels decrease allowing the Bcl-xL
equilibrium to shift favoring the cytosolic form, resulting in Bax
accumulation and activation on the mitochondria culminating
in apoptosis (Figure 6g). Future studies elucidating the
residues and upstream factors involved in regulating
CHCHD2–Bcl-xL binding will contribute to our understanding
of the anti-apoptotic function of CHCHD2.
In response to apoptotic stimuli, CHCHD2 level decreases
and loses its mitochondrial localization. The signals that
induce the loss of mitochondrial CHCHD2 are unknown, and
elucidating these triggers will be an important area for further
investigation. In other CHCH-domain-containing proteins, the
disulfide bonds between the cysteines of this domain can be
altered (generating various hairpin and oligomer formations)
depending on the oxidative-reductive state of the immediate
environment of the protein.26,45 One possibility that merits
further investigation is that the CHCH domain of CHCHD2
functions as a sensor of redox changes that take place at the
mitochondria during apoptosis, resulting in the appropriate
CHCHD2 conformational changes to regulate Bax oligomer-
ization and MOMP. Another possibility is that in addition to
regulating apoptosis at the mitochondrial membrane,
CHCHD2 may play an ancillary role in the cytoplasm and/or
nucleus. Indeed, a recent study reported that CHCHD2
functions as a transcription factor to regulate cytochrome c
oxidase expression and facilitate mitochondrial electron
transport chain flux.46 If so, our data indicate that such a role
may not be required for apoptosis, as siRNA-mediated
inhibition of CHCHD2 enhances rather than prevents
apoptosis.
Evasion of apoptosis is one of the hallmarks of cancer, and
cancers often exhibit reduced expression of pro-apoptotic
proteins and/or increased expression of anti-apoptotic
proteins.47,48 Based on the analysis of mRNA microarray
expression data obtained from the Oncomine database,
CHCHD2 is overexpressed in a diverse group of cancers,
including prostate, lung, kidney, skin, brain, mesothelium,
head and neck and two types of leukemias (Table 1).49–61 The
upregulation of CHCHD2 in cancers along with our data
showing that CHCHD2 knockdown sensitizes cancer cells to
chemotherapeutic agents suggests that further research
investigating CHCHD2 as a cancer biomarker or as a potential
chemosensitizing drug target may be warranted.
Materials and Methods
Cell culture, transfection, and apoptotic treatments. U2OS and
HeLa cells were obtained from ATCC (Manassas, VA, USA), and MEFs were
harvested at E13.5. All cells were cultured in a 37 °C incubator with 5% CO2 in
DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin. DNA transfections were carried out by using Fugene-6 or Fugene-
HD (Roche, Basel, Switzerland), and siRNA transfections were performed by using
Oligofectamine (Invitrogen) according to the instructions provided by the
manufacturer. Apoptosis treatments included UVC irradiation at the indicated dose
using a Stratalinker UV Crosslinker (Stratagene, Santa Clara, CA, USA), cisplatin
(10 μg/ml for U2OS and HeLa cells), doxorubicin (7.5 μM for U2OS cells) and
staurosporine (200 nM for U2OS cells). Where indicated, cells were pretreated for
1 h with the pan-caspase inhibitor QVD (R&D Systems, Minneapolis, MN, USA;
10 μM for U2OS and HeLa cells). Apoptosis was quantified by annexinV–FITC and
PI double staining using a kit from Life Technology Inc. (Grand Island, NY, USA).
Subcellular fractionation experiments were conducted as previously described.62
DNA plasmids, adenoviruses and siRNA. Full-length CHCHD2 cDNA
was purchased from Open Biosystems (Genbank accession number
NM_016139.2). Untagged and C-terminally FLAG-tagged CHCHD2 were cloned
into the pcDNA3.1 vector (Invitrogen). All cloned constructs were confirmed by DNA
sequencing. Recombinant adenoviruses carrying untagged CHCHD2 or GFP were
produced by using the AdEasy XL Adenoviral Vector System (Stratagene) according
to the manufacturer’s protocol. siRNA duplexes targeting CHCHD2 and Bcl-xL were
purchased from Invitrogen (Stealth RNAi targeting CHCHD2#1 5′-GGGCACACA
TTGGGTCACGCCATTA-3′, CHCHD2#2 5′-GGTGACATCAAGCTCTGTGAGGGTT-3′
and targeting Bcl-xL 5′-GGAGATGCAGGTATTGGTG-3′), and nonspecific control
siRNA was purchased from Dharmacon (Lafayette, CO, USA).
Western blotting and immunoprecipitation. After lysing cells in 0.5%
NP-40 buffer, the lysates were resolved on a 12.5% polyacrylamide gel and then
transferred to a 0.2-μm nitrocellulose membrane. Membranes were blocked for at
least 30 min in phosphate-buffered saline blocking buffer with 0.1% Tween-20
(PBST) and 5% non-fat dried milk. Membranes were incubated for 2 h to overnight
with the appropriate primary antibody, incubated for 1–2 h in secondary HRP-
conjugated antibody, and exposed with Supersignal West Pico or Dura reagent
(Pierce, Rockford, IL, USA). For CO-IP experiments, cells or crude mitochondria
were lysed in 1% CHAPS buffer (10 mM HEPES, 150 mM NaCl and 1% CHAPS
with protease inhibitor cocktail). Lysates containing 500 μg to 1 mg of protein were
immunoprecipitated with the indicated antibody. The precipitated protein was
resolved by SDS-PAGE and then analyzed by western blotting.
Immunofluorescence and confocal imaging. For immunofluorescence
imaging, cells were fixed in 4% paraformaldehyde for 15 min at room temperature




Breast, ductal carcinoma 1.754 4.10E− 10 Sorlie et al.49
Cervical cancer 1.656 2.00E− 03 Pyeon et al.50
Glioblastoma 1.579 5.57E− 05 Liang et al.51
Leukemia, acute myeloid 2.032 2.16E− 05 Andersson et al.52
Leukemia, childhood T-cell acute
lymphoblastic
2.913 1.56E− 05 Andersson et al.52
Lung adenocarcinoma 1.564 3.07E− 13 Landi et al.53
Lymphoma, diffuse B-cell 1.846 1.00E− 02 Storz et al.54
Melanoma 4.163 4.77E− 04 Haqq et al.55
Mesothelioma, pleural malignant 2.018 1.62E− 06 Gordon et al.56
Myeloma, smoldering 2.018 3.23E− 05 Zhan et al.57
Neuroblastoma 1.755 8.76E− 04 Albino et al.58
Oral cavity carcinoma 2.827 2.05E− 06 Pyeon et al.50
Oropharyngeal carcinoma 2.325 3.85E− 06 Pyeon et al.50
Pancreatic carcinoma 1.52 3.48E− 05 Pei et al.59
Prostate carcinoma 2.13 1.98E− 04 Tomlins et al.60
Renal cell carcinoma, papillary 1.591 1.30E− 04 Yusenko et al.61
Tongue carcinoma 2.231 1.12E− 05 Pyeon et al.50
Microarray data obtained from Oncomine (Compendia Bioscience, Ann Arbor,
MI, USA). Cancers with ≥ 1.5-fold increase in Sumi-1 expression and
P-value≤ 0.01 are shown
aCompared with expression in corresponding normal tissues
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and permeabilized in 0.2% Triton X-100 for 5 min at 4 °C. Fixed and permeabilized
cells were blocked for 30 min in 0.5% BSA blocking buffer diluted in PBS, incubated
with the appropriate primary antibody overnight at 4 °C with gentle shaking and then
incubated with Alexa Fluor secondary antibodies (488 nm and 594 nm donkey anti-
rabbit and donkey anti-mouse antibodies, respectively; Life Technology Inc.) for 1 h
at room temperature with gentle shaking. Nuclei were stained with 40 ,6-diamidino-2-
phenylindole (DAPI), and mitochondria visualized with MitoTracker Red or other
mitochondrial markers where indicated. Cells were mounted in fluorescence
mounting medium (Dako, Carpinteria, CA, USA) and were analyzed by using either
an Olympus FLUOVIEW FV1000 confocal laser scanning microscope or an
Olympus IX81 inverted microscope (Olympus Corporation, Tokyo, Japan) combined
with a SPOT digital microscope camera and imaging software (SPOT Imaging
Solutions, Sterling Heights, MI, USA) as indicated.
Antibodies. Rabbit anti-CHCHD2 antibody was produced by immunizing rabbits
(PRF&L, Canadensis, PA, USA) with a KLH-conjugated peptide antigen
corresponding to amino acids 94–108 of CHCHD2. Serum was affinity purified,
and antibody specificity was tested by western blotting and immunofluorescence
staining in the presence or absence of CHCHD2 knockdown. The following
antibodies were purchased commercially: actin (Chemicon, Billerica, MA, USA),
PARP (C2-10, BD Pharmingen, San Jose, CA, USA), mtHSP70/GRP75 (H-155,
Santa Cruz, Dallas, TX, USA), cytochrome c (6H2.B4, BD Pharmingen), active/
cleaved caspase-3 (Asp175, Cell Signaling, Danvers, MA, USA), Tim23 (BD
Transduction Laboratories, San Jose, CA, USA), Bcl-xL (sc-634, Santa Cruz), Bax
(BD Biosciences, San Jose, CA, USA), Bak (Abcam, Cambridge, MA, USA), active
Bax (6A7, BD Biosciences).
Bax trypsin resistance assay. The Bax trypsin resistance assay was
conducted as previously described40 with slight modifications. Briefly, mitochondria
were isolated by permeabilizing the cells in 0.015% digitonin in hypotonic buffer for
3 min at 4 °C followed by centrifugation at 12 000 × g for 10 min at 4 °C. The
resulting mitochondria-enriched pellet was incubated with trypsin (0.17 mg/ml) for
2 h at 30 °C followed by treatment with trypsin inhibitor (1.4 mg/ml, Sigma, St. Louis,
MO, USA). Trypsin-treated mitochondria were lysed in 0.5% Triton X-100 and
analyzed by immunoblotting alongside untreated whole-cell lysates.
Statistical analysis. Data were analyzed by using Graph Pad 5.0 software
(GraphPad Software, La Jolla, CA, USA). Error bars denote the S.E.M. Statistical
analyses were performed based on Student’s t-test, and P-valueso0.05 were
considered statistically significant (*, ** and *** are used to indicate statistical
significance corresponding to a P-valueo0.05, P-valueo0.01 and P-valueo0.001,
respectively). NS indicates no significant difference.
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